Tier 2 — strong

Isoquercetin for thromboinflammation in sickle cell disease: a randomized double-blind placebo-controlled trial

Maria A Lizarralde-Iragorri, Bindu Parachalil Gopalan, Brenda Merriweather, Jennifer Brooks, Mai Hill, Dianna Lovins, Ruth Pierre-Charles, Ann Cullinane, Alina Dulau-Florea, Duck-Yeon Lee, Rafael Villasmil, Neal Jeffries, Arun S Shet
Blood advances 2024 8(1):172-182

Bibliography

PubMed
PMID 38157227
PubMed Central
PMC10787266
DOI
10.1182/bloodadvances.2023011542
Funding
Indexed grant support: ZIA HL006256 — Intramural NIH HHS — United States; ZIA HL006241 — Intramural NIH HHS — United States. The indexed list may not contain the complete funding declaration.
Competing interests
Reported disclosure: Conflict-of-interest disclosure: The authors declare no competing financial interests.

Study snapshot

DesignRandomized double-blind placebo-controlled trial
ModelHuman intervention research
Sample46 adults with sickle cell disease; 23 per group
InterventionIsoquercetin versus placebo; fixed dose requires full methods
DurationShort-term intervention; duration not stated in abstract
EndpointsPlatelet or coagulation measurements

What the study showed, in plain terms

Published in 2024, this source examined cardiovascular and metabolic health. Design: Randomized double-blind placebo-controlled trial. Sample/model: 46 adults with sickle cell disease; 23 per group. The exposure or intervention was Isoquercetin versus placebo; fixed dose requires full methods. Follow-up or treatment period: Short-term intervention; duration not stated in abstract.

The primary soluble P-selectin endpoint did not differ between groups. Several coagulation and platelet measures decreased from baseline in the treated group.

Within-group biomarker changes are not proof of fewer thromboses. Isoquercetin is a distinct glycoside formulation.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Weight Loss, Blood Sugar and Fatty Liver: Human Evidence. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • The primary soluble P-selectin endpoint did not differ between groups.
  • Several coagulation and platelet measures decreased from baseline in the treated group.
  • The recorded outcome domains were Platelet or coagulation measurements.
  • The result applies to the tested exposure: Isoquercetin versus placebo; fixed dose requires full methods; Short-term intervention; duration not stated in abstract.

What this study can and cannot tell us

  • Within-group biomarker changes are not proof of fewer thromboses. Isoquercetin is a distinct glycoside formulation.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: accessible full text and indexed metadata. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Quercetins efficacy on bone and inflammatory markers, body composition, and physical function in postmenopausal women
Alyssa R Bailly et al. · Journal of bone and mineral metabolism · 2025
Tier 2
Quercetin Reduces Vascular Senescence and Inflammation in Symptomatic Male but Not Female Coronary Artery Disease Patients
Pauline Mury et al. · Aging cell · 2025
Tier 2
Impact of quercetin in patients with myocardial infarction. A multicenter, randomized, and open-label pilot study
Sergey Kozhukhov et al. · Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese · 2024

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology